Medistim

Earnings Release • Feb 28, 2025

Results for the fourth quarter and preliminary financial results for Medistim for 2024

Results for the fourth quarter and preliminary financial results for Medistim for 2024

All time high quarter for sales revenues, ending at MNOK 151.1, 11.4% above fourth quarter last year (MNOK 135.6). Full year sales ended at MNOK 562.6, 6.9% above last year (MNOK 526.4).

Currency neutral sales of own products was up 9.7% for the quarter and 3.9% for the full year.

Recurring sales remained high at 71.5% (71.3%) for the quarter and 73.7% (69.3%) for the year.

AMERICAS delivered a strong quarter with 29.7% currency neutral growth. EMEA showed strong performance with currency neutral growth of 10.9%. APAC was down 24.4% for the quarter.

Operating profit (EBIT) for the quarter ended at MNOK 25.8 giving a 17.1% EBIT margin (MNOK 22.3, a 16.4% margin). For the full year, EBIT was at MNOK 131,1 (MNOK 131.4) giving a 23.3% EBIT margin (25.0%).

Third-party distributor sales in Scandinavia increased 10.4% for the quarter and 13.1% for the year.

In December, Medistim launched its new MiraQ INTUI software platform for Cardiac surgery.

For vascular surgery, Medistim launched a multicenter study of TTFM and HFUS imaging as completion control in peripheral bypass.

Solid cash position at quarter end with MNOK 179.2 and no interest-bearing debt. The Board of Directors suggests a dividend of NOK 6.00 per share (NOK 4.5), total MNOK 109.8 (MNOK 82.4).